Tolerance and pharmacokinetic interactions of rifabutin and azithromycin.
This multicenter study evaluated the tolerance and potential pharmacokinetic interactions between azithromycin and rifabutin in volunteers with or without human immunodeficiency virus infection. Daily dosing with the combination of azithromycin and rifabutin was poorly tolerated, primarily because of gastrointestinal symptoms and neutropenia. No significant pharmacokinetic interactions were found between these drugs.
Hafner
R
R
Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. RHafner@niaid.nih.gov
Bethel
J
J
Standiford
H C
HC
Follansbee
S
S
Cohn
D L
DL
Polk
R E
RE
Mole
L
L
Raasch
R
R
Kumar
P
P
Mushatt
D
D
Drusano
G
G
D000328:Adult; D019540:Area Under Curve; D017963:Azithromycin / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology; D004338:Drug Combinations; D004347:Drug Interactions; D004359:Drug Therapy, Combination / Q000493:pharmacokinetics* / Q000494:pharmacology; D005260:Female; D015658:HIV Infections / Q000378:metabolism*; D006801:Humans; D008297:Male; D017828:Rifabutin / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology
D004338:Drug Combinations; D017828:Rifabutin; D017963:Azithromycin